![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif)
prostate cancer vaccine ONY-P1 A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon adminstration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif)
Foreign brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif) | Onyvax-P | | ![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif) | ONY-P1 | | ![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115003545im_/http://www.cancer.gov/images/spacer.gif) |